UAE Immuno-oncology Clinical Trials Market Size & Outlook

The immuno-oncology clinical trials market in the UAE is expected to reach a projected revenue of US$ 2.7 million by 2030. A compound annual growth rate of 12.1% is expected of the UAE immuno-oncology clinical trials market from 2024 to 2030.
Revenue, 2023 (US$M)
$1.2
Forecast, 2030 (US$M)
$2.7
CAGR, 2024 - 2030
12.3%
Report Coverage
UAE

UAE immuno-oncology clinical trials market, 2018-2030 (US$M)

UAE

UAE immuno-oncology clinical trials market highlights

  • The UAE immuno-oncology clinical trials market generated a revenue of USD 1.2 million in 2023 and is expected to reach USD 2.7 million by 2030.
  • The UAE market is expected to grow at a CAGR of 12.1% from 2024 to 2030.
  • In terms of segment, phase iii was the largest revenue generating phase in 2023.
  • Phase I is the most lucrative phase segment registering the fastest growth during the forecast period.


Immuno-oncology clinical trials market data book summary

Market revenue in 2023USD 1.2 million
Market revenue in 2030USD 2.7 million
Growth rate12.1% (CAGR from 2023 to 2030)
Largest segmentPhase iii
Fastest growing segmentPhase I
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationPhase I, Phase II, Phase III, Phase IV
Key market players worldwideMedpace Holdings Inc, Novartis AG ADR, Syneos Health, AstraZeneca PLC, Exscientia PLC ADR


Other key industry trends

  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Middle East & Africa, South Africa immuno-oncology clinical trials market is projected to lead the regional market in terms of revenue in 2030.
  • South Africa is the fastest growing regional market in Middle East & Africa and is projected to reach USD 65.9 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Immuno-oncology Clinical Trials Market Scope

Immuno-oncology clinical trials market segmentation & scope
Phase I
Phase II
Phase III
Phase IV
Interventional Trials
Observational Trials
Expanded Access Trials
Solid Tumors
Hematological Cancers

Immuno-oncology Clinical Trials Market Companies

Name Profile # Employees HQ Website

UAE immuno-oncology clinical trials market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immuno-oncology clinical trials market will help companies and investors design strategic landscapes.


Phase iii was the largest segment with a revenue share of 58.33% in 2023. Horizon Databook has segmented the UAE immuno-oncology clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to UAE immuno-oncology clinical trials market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of UAE immuno-oncology clinical trials market databook

  • Our clientele includes a mix of immuno-oncology clinical trials market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the UAE immuno-oncology clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into UAE immuno-oncology clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

UAE immuno-oncology clinical trials market size, by phase, 2018-2030 (US$M)

UAE Immuno-oncology Clinical Trials Market Outlook Share, 2023 & 2030 (US$M)

UAE immuno-oncology clinical trials market size, by phase, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more